Eli Lilly (LLY, Financial) shares surged around 14% in premarket trading Thursday after the company reported positive Phase 3 trial results for orforglipron, its once-daily oral GLP-1 drug for type 2 diabetes.
In its ACHIEVE-1 trial, the drug met its primary goal of reducing A1C—a key diabetes marker—by 1.3% to 1.6% across three dose levels from a baseline of 8.0%. The placebo group, by comparison, saw just a 0.1% reduction. Patients on the highest dose also lost an average of 16 pounds, or 7.9% of their body weight, without reaching a plateau by the 40-week mark.
Eli Lilly said the pill could be a scalable option for global use, pending regulatory approval. CEO David Ricks noted that the convenience of a daily oral medication may set it apart from injectables currently dominating the market.
Market reactions were swift: Novo Nordisk (NVO, Financial), Lilly's main GLP-1 competitor, dropped roughly 5%. Viking Therapeutics (VKTX, Financial) and Amgen (AMGN, Financial) also traded lower, while Structure Therapeutics (GPCR, Financial) rose about 8%. Hims & Hers Health declined 7%.
Mild to moderate gastrointestinal issues were the most common side effects, with an 8% dropout rate at the highest dose. Eli Lilly plans to file for regulatory approval in diabetes by 2026 and in obesity by late 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.